Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) combine the targeting
power of a mAb with the treatment power of a small
molecule drug. However, the conjugation process
introduces a new, reactive environment that impacts
the stability of the mAb. Furthermore, the addition of
a small molecule to a mAb impacts the stability of the
domain where conjugation takes place.
With the power of high-resolution nanoDSF data, it
is possible to assess not only the overall stability changes
that take place during conjugation, but also the specific
domain to which the drug is conjugated.
